ETHealthworld.com brings latest mayo clinic news, views and updates from all top sources for the Indian Health industry.
Experts explore 3-year clinical data on bimekizumab presented at the 2025 EADV and SHSA congresses, highlighting its durable and ...
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for LusvertikimabDevelopment built on strong ...
Canadians living with HS at risk of inequitable access to newly approved therapy, falling behind Australia, France, Germany, Scotland and other ...
UCB Canada Inc. is pleased to announce Health Canada has granted a Notice of Compliance (NOC) for PrBIMZELX® (bimekizumab injection) indicated for the treatment of adult patients with moderate to ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...
Good morning and good afternoon, everyone. Thank you for standing by, and thank you for joining our conference call to discuss our top line data for INF904 in HS and CSU. [Operator Instructions] And ...
Reduction of draining tunnels sustained to three years: Of patients who had at least one draining tunnel at baseline, 48.2% had none at one year, and 62.9% at three years* – indicating sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results